PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01899599
Recruitment Status : Active, not recruiting
First Posted : July 15, 2013
Last Update Posted : July 17, 2017
Information provided by (Responsible Party):
Glycotope GmbH

Brief Summary:
Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.

Condition or disease Intervention/treatment Phase
Ovarian Epithelial Cancer Recurrent Fallopian Tube Cancer Primary Peritoneal Cancer Drug: Gatipotuzumab Drug: Placebo Phase 2

Detailed Description:
The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response after 2nd to 4th line of chemotherapy in patients with epithelial ovarian or fallopian tube or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in a previous line, while the response to the most recent Pt-based chemotherapy must not have lasted more than 12 months. In addition the response between most recent 2 lines of chemotherapy prior start of study medication must not have lasted more than 12 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Study Start Date : September 2013
Actual Primary Completion Date : June 16, 2017
Estimated Study Completion Date : November 2017

Arm Intervention/treatment
Experimental: Gatipotuzumab
1700mg, i.v., q3w
Drug: Gatipotuzumab
start dose 500mg at C0D1 maintenance dose 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
Other Name: PankoMab-GEX

Placebo Comparator: Placebo
matching placebo
Drug: Placebo
start dose matching 500mg at C0D1 maintenance dose matching 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: from baseline till progression of disease or death ]
    PFS will be determined by radiographic progression based on modified RECIST 1.1 or death of any cause.

Secondary Outcome Measures :
  1. To assess the safety and tolerability of maintenance therapy with single-agent PankoMab-GEX™ compared to placebo in patients with metastatic or recurrent ovarian or fallopian tube carcinoma or primary peritoneal carcinoma. [ Time Frame: 3 weekly ]
    Safety will be determined on the occurrence of infusion-related reactions (IRR, treatment emergent adverse events (TEAE) and treatment emergent serious adverse events (TESAE.

  2. Patient reported outcome [ Time Frame: every 9 weeks ]
    To evaluate the quality of life (QoL) and other health and health-economy related outcomes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Female patients ≥18 years of age.
  2. Histologically-confirmed, TA-MUC1 positive, recurrent epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer with high-grade (grade 2 or 3) serous features or a serous component.
  3. Availability of tumor tissue samples (slices or block) for immune-histological confirmation of TA-MUC1 status (tissue samples may also be stored for other further specified biomarker assessments).
  4. Patients should have received at least 2 lines but not more than 5 lines of chemotherapy prior to start of maintenance treatment.
  5. Documented response to or stable disease following the most recent line of chemotherapy (any regimen and duration in accordance with local or international guidelines or within independent ethics committee [IEC] approved studies) and received last dose of said chemotherapy ≤6 weeks prior to randomization (response to prior chemotherapy is defined as a partial/complete response according to radiological response criteria and/or a confirmed decline in tumor marker CA125 ≥50% from the pretreatment value ≥2 × the upper limit of normal [ULN]; stable disease is defined as stable disease according to radiological response criteria with a confirmed lack of increase in tumor marker CA125 from the pretreatment value for patients who have a pretreatment value ≥2 × ULN and no clinical progression). CA125 prior to randomization must be below ULN or CA125 levels must not increase >15% within a time frame >7 days if above ULN.
  6. Progression-free interval of ≤12 months immediately preceding the chemotherapy to which the patient has just responded.
  7. Sensitive or resistant to the most recent platinum-based chemotherapy preceding the chemotherapy to which the patient has just responded (sensitive is thereby defined as a recurrence of disease >6 to ≤12 months after end of platinum-based chemotherapy and resistant is defined as a recurrence of disease ≤6 months after the end of platinum-based chemotherapy).
  8. ECOG performance status ≤1.
  9. Recovered from all chemotherapy-related toxicities to grade 1 or grade 0 according to the NCI CTCAE version 4.0, with the exception of alopecia (any grade) and peripheral neuropathy (≤grade 2).
  10. Adequate bone marrow and hepatic function at Screening:

    • Hemoglobin ≥9 g/dL
    • White blood cell count ≥3.0 × 109/L
    • Absolute neutrophil count ≥1.5 × 109/L
    • Platelet count ≥100 × 109/L
    • Aspartate aminotransferase and alanine aminotransferase <3 × ULN (<5 × ULN in case of liver metastases)
    • Bilirubin <1.5 × ULN (<3 × ULN in case of liver metastases)
    • Creatinine <1.5 × ULN.
  11. Any patient with childbearing potential (i.e., not surgically sterile or postmenopausal for >1 year) must use highly effective contraceptives with a Pearl index <1% according to the Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (CPMP/ICH/286/95) of the European Medicines Agency (EMA) (Note: although pregnancy is unlikely to occur in this patient population, any patient with childbearing potential will be withdrawn from the study in the event of pregnancy).
  12. Life expectancy >3 months.
  13. Ability and willingness to give written informed consent. -

Exclusion Criteria:

  1. Refractory to platinum-based chemotherapy (defined as remained progressive or became progressive under any previous platinum-based regimen).
  2. Progression-free interval of >12 months after the most recent antecedent platinum-based chemotherapy regimen.
  3. Concomitant anti-tumor therapy or immunotherapy.
  4. Treatment with monoclonal antibodies or investigational agents ≤30 days before randomization (Note: prior anti-MUC1 therapy is not permitted at any time).
  5. Limited-field radiotherapy ≤30 days before randomization (Note: extensive prior radiotherapy during or following the last line of chemotherapy is not permitted; radiotherapy prior to the last line of chemotherapy is permitted).
  6. Prior allergic reaction to a monoclonal antibody, grade 3 IRR or any grade 4 reaction to a monoclonal antibody.
  7. Known sensitivity to any component of the test product.
  8. Contraindication to the premedications used in this study (paracetamol/acetaminophen, H1 and/or H2 receptor antagonists, and steroids).
  9. Clinical evidence of brain metastasis or leptomeningeal involvement.
  10. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥ 5 years.
  11. Primary or secondary immune deficiency.
  12. Clinically active infections >grade 2 using NCI CTCAE v 4.0.
  13. Active hepatitis B or C or infection with human immunodeficiency virus (HIV).
  14. Myocardial infarction within 6 months prior to Screening.
  15. Symptomatic congestive heart failure (New York Heart Association grade 3 or 4), unstable angina pectoris within 6 months prior to Screening, significant cardiac arrhythmia or history of stroke or transient ischemic attack within 1 year prior to Screening.
  16. Prior or planned major surgery within 30 days prior to randomization and/or incomplete recovery from prior surgery.
  17. Concomitant use of systemic steroids, except for inhaled, topical or nasal application within 30 days prior to randomization (Note: steroids used for premedication are permitted).
  18. Active drug or alcohol abuse.
  19. Any uncontrolled medical condition that may put the patient at high risk during treatment with an investigational drug, including unstable diabetes mellitus, vena cava syndrome, or chronic symptomatic respiratory disease.
  20. Pregnancy or lactation.
  21. Legal incompetence, limited legal competence, or detainment in an institution for official or legal reasons.
  22. Receipt of any other investigational medicinal product within the last 30 days before randomization or any previous PankoMab-GEXTM administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01899599

  Show 50 Study Locations
Sponsors and Collaborators
Glycotope GmbH
Principal Investigator: Jonathan Ledermann, MD UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK

Responsible Party: Glycotope GmbH Identifier: NCT01899599     History of Changes
Other Study ID Numbers: GEXMab25201
2013-000931-28 ( EudraCT Number )
First Posted: July 15, 2013    Key Record Dates
Last Update Posted: July 17, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Fallopian Tube Neoplasms
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases